Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $0.43.

  • Catalyst Pharmaceuticals' EPS (Basic) rose 1621.62% to $0.43 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.79, marking a year-over-year increase of 4320.0%. This contributed to the annual value of $1.38 for FY2024, which is 10597.01% up from last year.
  • Catalyst Pharmaceuticals' EPS (Basic) amounted to $0.43 in Q3 2025, which was up 1621.62% from $0.43 recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' EPS (Basic) peaked at $0.47 during Q1 2025, and registered a low of -$0.29 during Q3 2023.
  • Moreover, its 5-year median value for EPS (Basic) was $0.24 (2022), whereas its average is $0.24.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' EPS (Basic) plummeted by 23181.82% in 2023, and later skyrocketed by 22758.62% in 2024.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' EPS (Basic) stood at $0.09 in 2021, then skyrocketed by 166.67% to $0.24 in 2022, then skyrocketed by 37.5% to $0.33 in 2023, then skyrocketed by 39.39% to $0.46 in 2024, then dropped by 6.52% to $0.43 in 2025.
  • Its EPS (Basic) stands at $0.43 for Q3 2025, versus $0.43 for Q2 2025 and $0.47 for Q1 2025.